Patents by Inventor Joon Hun Choi

Joon Hun Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
    Patent number: 9814784
    Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: November 14, 2017
    Assignee: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Minseob Lee, Yeon Jung Kim, Kyoung Suk Kim, Joon hun Choi, Jin Seo Lee, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Matthew Sangyup Lee, In-Suk Lee, Joon woo Kim, Seung Suh Hong
  • Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
    Patent number: 9278996
    Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: March 8, 2016
    Assignee: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Min Seob Lee, Joon hun Choi, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Seung Suh Hong
  • ANTIBODY-LINKER-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND ANTICANCER DRUG COMPOSITION CONTAINING SAME
    Publication number: 20150366990
    Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
    Type: Application
    Filed: January 2, 2014
    Publication date: December 24, 2015
    Inventors: Young Jun PARK, Jin-kyo JEONG, Young Mi CHOI, Minseob LEE, Yeon Jung KIM, Kyoung Suk KIM, Joon hun CHOI, Jin Seo LEE, Eun Joo CHO, Hyunnam SONG, Sung Jun PARK, Jong-hyoup LEE, Matthew Sangyup LEE, In-Suk LEE, Joon woo KIN, Seung Suh HONG
  • DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME
    Publication number: 20150225455
    Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 13, 2015
    Applicant: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Min Seob Lee, Joon hun Choi, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Seung Suh Hong
  • 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
    Publication number: 20130245066
    Abstract: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 receptor or both.
    Type: Application
    Filed: June 22, 2011
    Publication date: September 19, 2013
    Applicants: IN2GEN CO., LTD., EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION, SK CHEMICALS CO., LTD.
    Inventors: Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, II-Sang Cho, Myoung-Soon Park, Young Jae An, Joon Hun Choi
  • 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
    Patent number: 8420685
    Abstract: A compound of the formula: Wherein A1, A2, X, R2 and R3 are as defined herein, or a composition containing the same, which compound is useful in treating renal-, liver- or pulmonary fibrosis.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: April 16, 2013
    Assignees: SK Chemicals Co., Ltd., Ewha University Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, Ii-Sang Cho, Myoung-Soon Park, Young Jae An, Joon Hun Choi
  • 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
    Publication number: 20080319022
    Abstract: 2-pyridyl-substituted imidazoles and their use in inhibiting ALK 5 and/or ALK 4 receptors is disclosed.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 25, 2008
    Applicants: IN2GEN CO., LTD., SK CHEMICALS CO., LTD., EWHA UNIVERSITY INDUSTRY
    Inventors: Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, Il-Sang Cho, Myoung-Soon Park, Young Jae An, Joon Hun Choi
  • 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
    Publication number: 20080319012
    Abstract: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 receptor or both.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 25, 2008
    Applicants: IN2GEN CO., LTD., SK CHEMICALS CO., LTD, EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, Il-Sang Cho, Myoung-Soon Park, Young Jae An, Joon Hun Choi
  • 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
    Patent number: 7407958
    Abstract: Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-? and/or activin signaling pathway in mammals.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: August 5, 2008
    Assignees: SK Chemicals Co., Ltd., EWHA University Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yung-Jue Bang, Hun-Taek Kim, Il-Sang Cho, Myoung-Soon Park, Young Jae An, Joon Hun Choi